letrozole has been researched along with Experimental Mammary Neoplasms in 20 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Letrozole was subcutaneously injected daily for 23 days at a dose of 1." | 5.43 | Effects of letrozole on breast cancer micro-metastatic tumor growth in bone and lung in mice inoculated with murine 4T1 cells. ( Belosay, A; Churchwell, MI; Doerge, DR; Hartman, JA; Helferich, WG; Iwaniec, UT; Song, H; Turner, RT; Wang, W; Yang, X, 2016) |
| "When letrozole was combined with the pure antiestrogen fulvestrant, which down-regulates ER, the combination was extremely effective." | 2.43 | Therapeutic observations in MCF-7 aromatase xenografts. ( Brodie, A; Goloubeva, O; Jelovac, D; Macedo, L; Sabnis, G; Tilghman, S, 2005) |
| "Letrozole was subcutaneously injected daily for 23 days at a dose of 1." | 1.43 | Effects of letrozole on breast cancer micro-metastatic tumor growth in bone and lung in mice inoculated with murine 4T1 cells. ( Belosay, A; Churchwell, MI; Doerge, DR; Hartman, JA; Helferich, WG; Iwaniec, UT; Song, H; Turner, RT; Wang, W; Yang, X, 2016) |
| "In letrozole - treated animals in comparison with untreated animals, increased plasmatic triacylglycerol concentrations (P<0." | 1.35 | Preventive effects of letrozole in the model of premenopausal mammary carcinogenesis. ( Fetisovova, Z; Kajo, K; Kubatka, P; Nosalova, G; Sadlonova, V, 2008) |
| "Letrozole was also effective in tumors failing to respond to tamoxifen, consistent with clinical findings." | 1.31 | Aromatase and COX-2 expression in human breast cancers. ( Blankenstein, MA; Blijham, GH; Brodie, AM; Chen, T; DeJong, PC; Elbers, JR; Fulton, A; Long, BJ; Lu, Q; Macpherson, N; Nortier, JW; Schipper, ME; Slee, PH; Thijssen, JH; van de Ven, J; van Gorp, JM, 2001) |
| "Letrozole was found to be a highly potent inhibitor of tumor proliferation and more effective than tamoxifen." | 1.30 | Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. ( Brodie, A; Liu, Y; Long, B; Lu, Q; Wang, JP; Yue, W, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (35.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 6 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Isanejad, A | 1 |
| Alizadeh, AM | 1 |
| Amani Shalamzari, S | 1 |
| Khodayari, H | 1 |
| Khodayari, S | 1 |
| Khori, V | 1 |
| Khojastehnjad, N | 1 |
| Wang, W | 1 |
| Belosay, A | 1 |
| Yang, X | 1 |
| Hartman, JA | 1 |
| Song, H | 1 |
| Iwaniec, UT | 1 |
| Turner, RT | 1 |
| Churchwell, MI | 1 |
| Doerge, DR | 1 |
| Helferich, WG | 1 |
| Yue, W | 4 |
| Wang, JP | 2 |
| Li, Y | 1 |
| Fan, P | 1 |
| Liu, G | 1 |
| Zhang, N | 1 |
| Conaway, M | 1 |
| Wang, H | 1 |
| Korach, KS | 1 |
| Bocchinfuso, W | 1 |
| Santen, R | 1 |
| Banerjee, S | 1 |
| A'Hern, R | 1 |
| Detre, S | 1 |
| Littlewood-Evans, AJ | 1 |
| Evans, DB | 1 |
| Dowsett, M | 1 |
| Martin, LA | 1 |
| Swami, S | 1 |
| Krishnan, AV | 1 |
| Wang, JY | 1 |
| Jensen, K | 1 |
| Peng, L | 1 |
| Albertelli, MA | 1 |
| Feldman, D | 1 |
| Hou, X | 1 |
| Huang, F | 1 |
| Macedo, LF | 1 |
| Harrington, SC | 1 |
| Reeves, KA | 1 |
| Greer, A | 1 |
| Finckenstein, FG | 1 |
| Brodie, A | 6 |
| Gottardis, MM | 1 |
| Carboni, JM | 1 |
| Haluska, P | 1 |
| Long, BJ | 3 |
| Jelovac, D | 3 |
| Thiantanawat, A | 1 |
| Brodie, AM | 2 |
| Brodie, AH | 1 |
| Long, B | 3 |
| Luthra, R | 1 |
| Kirma, N | 3 |
| Jones, J | 1 |
| Tekmal, RR | 3 |
| Macedo, L | 1 |
| Sabnis, G | 1 |
| Tilghman, S | 1 |
| Goloubeva, O | 1 |
| Kubatka, P | 1 |
| Sadlonova, V | 1 |
| Kajo, K | 1 |
| Nosalova, G | 1 |
| Fetisovova, Z | 1 |
| Wang, J | 2 |
| Savinov, A | 1 |
| Schieweck, K | 2 |
| Bhatnagar, AS | 2 |
| Batzl, C | 1 |
| Lang, M | 2 |
| Lu, Q | 4 |
| Liu, Y | 3 |
| Grigoryev, D | 1 |
| Gimbel, M | 1 |
| Gill, K | 1 |
| Fowler, K | 1 |
| Mandava, U | 1 |
| Fulton, A | 1 |
| Chen, T | 1 |
| Macpherson, N | 1 |
| DeJong, PC | 1 |
| Blankenstein, MA | 1 |
| Nortier, JW | 1 |
| Slee, PH | 1 |
| van de Ven, J | 1 |
| van Gorp, JM | 1 |
| Elbers, JR | 1 |
| Schipper, ME | 1 |
| Blijham, GH | 1 |
| Thijssen, JH | 1 |
| Häusler, A | 1 |
| Bowman, R | 1 |
2 reviews available for letrozole and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Therapeutic observations in MCF-7 aromatase xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Aromatase Inhibitors; Disease Mo | 2005 |
Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aromatase Inhibitors; Estro | 1990 |
18 other studies available for letrozole and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
MicroRNA-206, let-7a and microRNA-21 pathways involved in the anti-angiogenesis effects of the interval exercise training and hormone therapy in breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Combined Modality Thera | 2016 |
Effects of letrozole on breast cancer micro-metastatic tumor growth in bone and lung in mice inoculated with murine 4T1 cells.
Topics: Animals; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Female; Humans; L | 2016 |
Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Estradiol; Est | 2010 |
Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Aromatase; Aromatase Inhibitors; | 2010 |
Inhibitory effects of calcitriol on the growth of MCF-7 breast cancer xenografts in nude mice: selective modulation of aromatase expression in vivo.
Topics: Anastrozole; Animals; Aromatase; Aromatase Inhibitors; Calcitriol; Cell Line, Tumor; Cell Proliferat | 2011 |
Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Blotting, | 2011 |
The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Topics: Animals; Aromatase; Aromatase Inhibitors; Disease Models, Animal; Enzyme Inhibitors; Estradiol; Estr | 2002 |
The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens.
Topics: Androstadienes; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Cell | 2003 |
Use of letrozole as a chemopreventive agent in aromatase overexpressing transgenic mice.
Topics: Animals; Anticarcinogenic Agents; Aromatase; Aromatase Inhibitors; Birth Weight; Female; Hyperplasia | 2003 |
Preventive effects of letrozole in the model of premenopausal mammary carcinogenesis.
Topics: Animals; Anticarcinogenic Agents; Body Weight; Drug Screening Assays, Antitumor; Female; Letrozole; | 2008 |
Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model.
Topics: Androstenedione; Animals; Antineoplastic Agents; Aromatase Inhibitors; Cell Division; Fadrozole; Fem | 1995 |
Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Aromatase Inhibitors; Estradiol; Female; Letrozole; Lutei | 1993 |
Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 1998 |
The effects of aromatase inhibitors and antiestrogens in the nude mouse model.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Enzyme Inhibitors; Estr | 1998 |
The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
Topics: Analysis of Variance; Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 1999 |
Aromatase overexpression and breast hyperplasia, an in vivo model--continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands.
Topics: Animals; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors | 1999 |
Aromatase overexpression transgenic mice model: cell type specific expression and use of letrozole to abrogate mammary hyperplasia without affecting normal physiology.
Topics: Animals; Aromatase; Aromatase Inhibitors; Enzyme Inhibitors; Epithelial Cells; Estradiol; Estrogens; | 2001 |
Aromatase and COX-2 expression in human breast cancers.
Topics: Adipocytes; Adult; Aged; Aged, 80 and over; Animals; Aromatase; Aromatase Inhibitors; Breast Neoplas | 2001 |